Bicara Therapeutics (NASDAQ:BCAX) COO Sells $15,544.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 536 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $29.00, for a total transaction of $15,544.00. Following the sale, the chief operating officer owned 181,641 shares in the company, valued at $5,267,589. The trade was a 0.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.29, for a total transaction of $253,625.00.
• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.01, for a total transaction of $287,625.00.

Bicara Therapeutics Stock Performance

BCAX stock opened at $28.91 on Monday. The company has a market cap of $1.90 billion, a P/E ratio of -10.40 and a beta of -0.81. Bicara Therapeutics Inc. has a 52 week low of $9.47 and a 52 week high of $30.99. The company’s 50-day moving average price is $23.43 and its 200 day moving average price is $20.11.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, equities research analysts expect that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BCAX shares. HC Wainwright lifted their price objective on Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley upped their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Bank of America started coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Finally, Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.27.

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Siren L.L.C. increased its position in Bicara Therapeutics by 11.2% during the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after buying an additional 586,001 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after acquiring an additional 100,000 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Bicara Therapeutics by 26.2% in the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after acquiring an additional 692,933 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after acquiring an additional 2,771,868 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Bicara Therapeutics by 9.8% during the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after acquiring an additional 195,667 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.